Dr. Reddy’s launches generic epilepsy treatment
Dr. Reddy’s Labs has introduced its generic levetiracetam in sodium chloride injection. The drug, a generic of HQ Specialty Pharma’s product, is indicated to as an antiepileptic for patients ages 16 years and older for whom oral administration is temporarily not feasible. It also is indicated as an adjunctive treatment for partial onset seizures in adults with epilepsy.
Dr. Reddy’s generic will be available in 500 mg/100 ml, 1,000 mg/100 ml and 1,500 mg/100 ml single-dose infusion bags. The product had annual U.S. sales of roughly $37 million, according to IQVIA data for the 12 months ended April 2018.
Dr. Reddy’s generic will be available in 500 mg/100 ml, 1,000 mg/100 ml and 1,500 mg/100 ml single-dose infusion bags. The product had annual U.S. sales of roughly $37 million, according to IQVIA data for the 12 months ended April 2018.